Hydrophobic Interaction Chromatography Market Trends

Growth Drivers

• Growing Development of Monoclonal Antibodies – At least 570 therapeutic mAbs have been researched in clinical trials by commercial businesses around the world, and 79 therapeutic mAbs have been licensed and are currently on the market by the United States Food and Drug Administration (US FDA). Hydrophobic interaction chromatography is an essential part of the development of Mabs, as they are used for its analysis and final purification.
• Rising Expenditure on Biopharmaceutical R&D –The increased spending on biopharmaceutical research and development, and production leads to a higher generation of new drugs and treatments. In the developmental stage of these drugs, HIC segregates the target molecules from the complex mixtures and helps them meet the regulatory requirements. In 2021, the 15 major pharmaceutical companies in the United States invested a record around USD 133 billion in R&D, approximately a 44% increase over 2016.
• Rising Cases of Cancer–HIC is used for the characterization and quality of control of cancer treatment therapeutic proteins. Therefore, the rising cases of cancer are driving the market growth. Cancer is one of the leading causes of death on the globe. Moreover, every year, around 400 000 children are identified as cancer patients.

Challenges

• Hydrophobic Interaction Chromatography is Expensive – HIC has various components, such as chromatography column, detectors, and systems, that is costly to acquire and maintain. Moreover, other consumables, including resin and buffers can also put a burden on the overall expense. Therefore, all these expenditures, particularly for a small organization, are likely to hamper the hydrophobic interaction chromatography market growth.
• Lack of highly qualified technicians and researchers
• Low adoption of technique in the under-developed countries